Compare QUBT & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QUBT | GENB |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2019 | 2026 |
| Metric | QUBT | GENB |
|---|---|---|
| Price | $6.86 | $14.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $18.67 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 6.4M | 956.5K |
| Earning Date | 11-09-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $682,000.00 | N/A |
| Revenue This Year | $4,100.54 | N/A |
| Revenue Next Year | $74.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.84 | N/A |
| 52 Week Low | $5.39 | $11.00 |
| 52 Week High | $14.45 | $22.67 |
| Indicator | QUBT | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 51.96 |
| Support Level | $6.13 | $11.82 |
| Resistance Level | $6.98 | $14.29 |
| Average True Range (ATR) | 0.42 | 1.07 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 91.28 | 46.71 |
Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.